SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
FDA, Clinical Trial Calendar Updates: WYE, SVNT, AMRN, ISIS, SLXP, SOMX
ISIS
|
|
|
-9.89%
in
188 days
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo...
|
FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson
ISIS
|
|
|
-5.99%
in
15 days
(closed on 05/07/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete r...
|
Top 40 Rated Emerging Bio-Pharma Stocks
ISIS
|
|
|
+17.78%
in
120 days
(closed on 04/22/09)
<> 
The accompanying table [click to enlarge] highlights the Top 40 Rated stocks (sorted alphabetically) in the ETF Innovators [ETFI] Emerging Bio-Pharma Index of biotech and pharmaceutical companies with market caps of $200M-$1.5B. The rating system factors in each company's number of innovative clinical pipeline + marketed products, market cap weighting, and historical stock price return.
The Emerging Bio-Pharma Index has outpaced benchmark ETFs such as iShares Nasdaq Biotech (IBB), PowerShares Dynamic Pharma (PJP),...
|
A New Index of Emerging Biotech & Pharma Companies
ISIS
|
|
|
+25.67%
in
30 days
(closed on 12/22/08)
<> 
<>
The accompanying table includes the Top 40 rated companies in the ETF Innovators [ETFI] Emerging Bio-Pharma Index, which includes U.S.-listed companies with market caps between $150M-$1.5B and factors in each companies approved products, late-stage clinical pipeline, trailing 52-week stock price performance, and market cap weighting to calculate a stock rating.
The index has performed much better than its peers over the past year for both the Top 40 Rated (-9%) and all 76 companies (-15%) – doing bett< />< /><><>< />< /><>...
|
Who's Next in the Biotech Buyout Frenzy?
ISIS
|
|
|
-15.06%
in
40 days
(closed on 11/22/08)
<> The biotech industry is rapidly consolidating as big pharma companies put their cash stash to use in deals ranging from well-known large caps all the way down to unknown micro-caps in an effort to bolster their range of marketed products, late stage pipeline candidates, and drug discovery technology platforms.
Genentech (DNA) has rejected Roche's (RHHBY) $89 bid to acquire the remaining 44% of DNA it does not already own as insufficient. I think DNA could easily get $100 per share based on Eli Lilly's (LLY) $70 buyout of ImClo...
|
From the Blogosphere
Three Core Biotech Holdings: Isis, Ligand and Vical
Isis (ISIS), Ligand (LGND) and Vical (VICL) have been my core biotech holdings since the mid 1990s and I have been steadily adding to these positions each time the market has lost faith. They share common themes and some differences. Isis and Vical have maintained consistent management throughout the years, whereas Ligand radically changed direction a few years ago when Daniel Loeb’s Third Point hedge fund took a stake. Now all three are focused on drug discovery; leaving the marketing to others. <>All three have many pharmaceutical partnerships and many shots on goal, so one failure would n...
|
3 Biotechs, 3 Big Pharma Plays for the Coming Generics Boom
<>I recently highlighted a small biotech firm, ISIS Pharmaceuticals, as a potential “value” growth play. ISIS (ISIS) took a tumble after earnings despite being just a penny off of estimates. Despite slightly lower than expected earnings, the Company showed a strong cash position, moderate cash burn, and a likelihood that it would be able to at least make it through full trials for its most promising drug. I know that for some even this doesn’t count as value. Afterall, the Company is not free cash positive and any value ascribed to the Company is derived from future expectations of its ...
|
ISIS Makes (Anti) Sense (and Value)
Since bottoming near the end of 2008, ISIS Pharmaceuticals (ISIS) has been one of the hottest stocks in the first half of 2009. 
|
The 'Micropsia' Group: 8 Healthcare Stocks Bullish in Some Time Frame
<>The micropsia sequence of posts was not really fair, mostly because I revealed few items, if any [click links for posts, in order]. But now has come the moment to reveal several items. First, the companies (in order of presentation)...
1) BioDelivery Sciences (BDSI)
2) Spectrum Pharmaceuticals (SPPI)
3) OncoGenex Pharmaceuticals (OGXI)
4) Vion Pharmaceuticals (VION)
5) Isis Pharmaceuticals (ISIS)
6) Johnson & Johnson (JNJ)
7) Volcano (VOLC)
8) Thoratec (THOR)
You will discern rather quickly my second 'revelation' -- the obvious fact that all eight companies derive from one key market sector, health ...
|
Isis Generating Impressive Oncology, Diabetes Data
By Jason Napodano, CFA At perhaps the two biggest industry trade conferences of the year, the American Society of Clinical Oncology ((ASCO)) and the American Diabetes Association ((ADA)), Isis Pharmaceuticals (ISIS) and/or its partners presented encouraging pre-clinical and early-stage clinical data showing the potential power of antisense technology as a new paradigm for treating cancer and diabetes -- two of the most widespread diseases in the U.S. and worldwide.
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on ISIS |
Visit streetinsider.com
|
|
|
|
uk
(-2.82% risk: moderate)
|
|
|
More Resources
|
About Isis Pharmaceuticals Inc.
- Answers.com
